OrbitonOpen research workspace →
NRx Pharmaceuticals, Inc. logo

NRx Pharmaceuticals, Inc.

NASDAQ:NRXPLive AI agent

NRx Pharmaceuticals is a pioneering CNS biopharma company focused on addressing unmet medical needs for conditions such as suicidal depression, suicidal bipolar depression, and PTSD.

Investor website: https://nrxpharma.com/

About

NRx Pharmaceuticals is a pioneering CNS biopharma company focused on addressing unmet medical needs for conditions such as suicidal depression, suicidal bipolar depression, and PTSD. The company has filed an ANDA for NRX-100, a preservative-free IV ketamine, and is working on an NDA for the same in patients with suicidal depression. NRx aims to tackle life-threatening diseases through research, development, and scaling of medical solutions, leveraging proven science and clinical expertise.

Verified company data

Cash position
$27.6 million
Shares outstanding
66,641,314
Projects
["NRX-101 is a patented, fixed dose combination product of D-cycloserine and lurasidone; both are approved drugs that have not shown abuse potential. It is estimated that up to 50% of individuals with bipolar disorders attempt suicide or have serious thoughts of suicide over their lifetime. NRx Pharmaceuticals plans to start an NRX-101 Phase IIb/III registrational trial in patients with bipolar depression and acute suicidal ideation and behavior (ASIB) (requiring hospitalization) later this year."]
Leadership
Joshua Brown, MD, PhD (Chief Medical Innovation Officer, Psychiatrist, neurologist, and neuroscientist with expertise in Transcranial Magnetic Stimulation (TMS) and clinical optimization. Medical Director of the McLean Hospital TMS Service and founding director of the Brain Stimulation Mechanisms Laboratory.), Glenn D. Tyson (Chief Commercial Officer, 25 years of experience in the pharmaceutical industry, previously served at GSK and Indivior, focusing on commercialization and sales for psychiatric conditions.), Rebecca S. Cohen, MD, FAPA, FCTMSS (Medical Director, Interventional Psychiatrist and Psychopharmacologist specializing in mood and anxiety disorders, founder of one of the first interventional psychiatry practices in the U.S.), Michael Taylor (Chief Development Officer, Over 25 years of experience in global credit markets, specializing in complex debt structuring and capital formation.), Michael Abrams (Chief Financial Officer, Senior finance professional with nearly 30 years of experience in executive roles and investment banking.), Jonathan C. Javitt, M.D., M.P.H. (Founder, Chairman & Chief Scientist; Co-CEO HOPE Therapeutics, Founder of seven successful healthcare IT and biopharma startups, with extensive experience in drug development and health IT policy.), Philip T. Lavin, Ph.D. (Chief Methodologist, Biostatistician with over 30 years of experience in clinical trial design and analysis, co-founder of Boston Biostatistics.), Dennis K. McBride, Ph.D. (Chief Strategy Officer, Expert in neuroscience and medical technology, with a distinguished career in the federal government and academia.), Chaim Hurvitz (Chief Executive Officer of CH Health, former President of Teva International Group, with extensive experience in the pharmaceutical industry.), Hon. Sherry A. Glied, Ph.D. (Dean of NYU’s Wagner Graduate School of Public Service, expert in health policy reform and former Assistant Secretary for Planning and Evaluation at HHS.), Patrick Flynn (Audit Committee Chair, Entrepreneur with over 30 years of executive experience, currently COO of Good Measures, Inc.), Aaron Gorovitz, J.D. (Partner of the AHG Group, with 25 years of legal experience in complex commercial transactions and biotechnology.)

Verified data last updated:

Recent filings